CompletedPhase 3

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

United States55 participantsStarted 2017-09-19

Plain-language summary

The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake, and 3) examines a genetic predisposition that may markedly impact the effectiveness of this medication in those at high risk for T2DM.

Who can participate

Age range18 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Baseline BMI between 25 and 35 Exclusion Criteria: * Individuals with current fMRI contraindications (e.g., metal implants, braces) * Probable current Axis I psychopathology (e.g., major depression disorder, panic disorder, generalized anxiety disorder, bipolar disorder) * Habitual use of cigarettes or illicit drugs * Pregnancy or breastfeeding * Diagnosis of serious medical problems (e.g., diabetes, cardiovascular disease, stroke) * Current weight loss dieting and/or weight fluctuations great than 10 lbs in the previous 6 weeks * Do not consume dairy * Allergy to bromocriptine, dairy, and nuts

What they're measuring

Ad Libitum Food and Beverage Intake (g)

Timeframe: Within 15 minutes of completion of the ad libitum period

Hedonic Ratings of Food as Measured by a Visual Analog Scale

Timeframe: Up to 5 minutes prior to ad libitum period start

Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water

Timeframe: Baseline and 2 Weeks

Trial details

NCT IDNCT05405244

SponsorUniversity of North Carolina, Chapel Hill

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-09-19

Results submitted2022-06-14

View on ClinicalTrials.gov More Overweight and Obesity trials